<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/379j–41" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/379j–41/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/379j–41/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_379j_41"><akn:num>379j–41</akn:num><akn:heading>Definitions</akn:heading><akn:content><akn:p>§ 379j–41. Definitions
For purposes of this subpart:(1) The term “abbreviated new drug application”—(A) means an application submitted under section 355(j) of this title, an abbreviated application submitted under section 357 of this title (as in effect on the day before November 21, 1997), or an abbreviated new drug application submitted pursuant to regulations in effect prior to the implementation of the Drug Price Competition and Patent Term Restoration Act of 1984; and

(B) does not include an application—(i) for a positron emission tomography drug; or

(ii) submitted by a State or Federal governmental entity for a drug that is not distributed commercially.



(2) The term “active pharmaceutical ingredient” means—(A) a substance, or a mixture when the substance is unstable or cannot be transported on its own, intended—(i) to be used as a component of a drug; and

(ii) to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the human body; or


(B) a substance intended for final crystallization, purification, or salt formation, or any combination of those activities, to become a substance or mixture described in subparagraph (A).


(3) The term “adjustment factor” means a factor applicable to a fiscal year that is the Consumer Price Index for all urban consumers (all items; United States city average) for October of the preceding fiscal year divided by such Index for October 2011.

(4) The term “affiliate” means a business entity that has a relationship with a second business entity if, directly or indirectly—(A) one business entity controls, or has the power to control, the other business entity; or

(B) a third party controls, or has power to control, both of the business entities.


(5) The term “contract manufacturing organization facility” means a manufacturing facility of a finished dosage form of a drug approved pursuant to an abbreviat</akn:p></akn:content><akn:subsection eId="subsec_379j_41_1"><akn:num>(1)</akn:num><akn:content><akn:p>(1) The term “abbreviated new drug application”—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_41_2"><akn:num>(2)</akn:num><akn:content><akn:p>(2) The term “active pharmaceutical ingredient” means—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_41_3"><akn:num>(3)</akn:num><akn:content><akn:p>(3) The term “adjustment factor” means a factor applicable to a fiscal year that is the Consumer Price Index for all urban consumers (all items; United States city average) for October of the preceding fiscal year divided by such Index for October 2011.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_41_4"><akn:num>(4)</akn:num><akn:content><akn:p>(4) The term “affiliate” means a business entity that has a relationship with a second business entity if, directly or indirectly—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_41_5"><akn:num>(5)</akn:num><akn:content><akn:p>(5) The term “contract manufacturing organization facility” means a manufacturing facility of a finished dosage form of a drug approved pursuant to an abbreviated new drug application, where such manufacturing facility is not identified in an approved abbreviated new drug application held by the owner of such facility or an affiliate of such owner or facility.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_41_6"><akn:num>(6)</akn:num><akn:content><akn:p>(6)</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_41_7"><akn:num>(7)</akn:num><akn:content><akn:p>(7) The term “finished dosage form” means—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_41_8"><akn:num>(8)</akn:num><akn:content><akn:p>(8) The term “generic drug submission” means an abbreviated new drug application, an amendment to an abbreviated new drug application, or a prior approval supplement to an abbreviated new drug application.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_41_9"><akn:num>(9)</akn:num><akn:content><akn:p>(9) The term “human generic drug activities” means the following activities of the Secretary associated with generic drugs and inspection of facilities associated with generic drugs:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_41_10"><akn:num>(10)</akn:num><akn:content><akn:p>(10) The term “positron emission tomography drug” has the meaning given to the term “compounded positron emission tomography drug” in section 321(ii) of this title, except that paragraph (1)(B) of such section shall not apply.</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>